In silico Repositioning of Alendronate and Cytarabine Drugs to Cure Mutations of FPPS, HAP, PTPRS, PTPRE, PTN4, GGPPS Gene and Mutant DNA, DPOLB, TOP2a, DPOLA, DNMT, RNA, TYSY, RIR Genes

Osteoporosis occurs because of the Calcitonin-Related Polypeptide Alpha (CALCA) gene. At present, Caltrate600, Boniva and Alendronate are viewed as dynamic drugs to cure osteoporosis. Chronic lymphocytic leukemia occurs because of the ABL1 proto oncogene. Currently, Rituximab, Fludarabine and Cytarabine are utilized as monoclonal antibodies against this ailment. Drug repositioning is a new rising field of reusing previous drugs, safeguarding retired drugs and developing licenses to make lives easy. The main objective of this research was repositioning of Alendronate and Cytarabine in order to use them in other diseases, too. Interactions of each of these drugs with many off-target proteins were identified. Alendronate presented strong interactions with FPPS, Hydroxylapatite, PTPRS, PTPRE, PTN4 and GGPPS. Cytarabine demonstrated strong interactions with DNA and DPOLB. After screening a great number of drugs which are accustomed to cure mutations of those off-target genes and proteins, their ill effects were compared, and it is suggested that Alendronate and Cytarabine have less side effects than different other drugs utilized for the same interacting targets. Both Alendronate and Cytarabine can be repositioned to cure well known carcinomas and different diseases.